Navigation Links
Oncothyreon announces prioritization plan for development programs
Date:9/2/2008

SEATTLE, Sept. 2 /PRNewswire-FirstCall/ - Oncothyreon Inc. (NASDAQ: ONTY) (TSX: ONY) (the "Company") today announced a prioritization plan to focus the Company's resources on the clinical development of PX-478 and PX-866 and on process development and manufacturing of Stimuvax(R). Oncothyreon will seek a partner for further clinical development of PX-12 beyond the ongoing trials. The prioritization plan is intended to concentrate Oncothyreon's efforts and available resources on those programs with the potential for the greatest near-term value creation for the Company's stockholders.

"This prioritization plan and the planned financing we also announced today are intended to make it possible for us to advance both PX-478 and PX-866 to the next stage of clinical development," said Robert L. Kirkman, M.D., President and Chief Executive Officer of Oncothyreon. "The ongoing dose escalation Phase 1 trial for PX-478, an inhibitor of hypoxia-inducible factor 1 alpha, is enrolling steadily and has not yet reached a maximum dose. The recently initiated Phase 1 trial for PX-866, an inhibitor of PI-3-kinase, is also enrolling well. We believe the high interest in the targets of these two compounds by both oncologists and potential partners will allow us to create value most effectively and quickly by concentrating our limited resources on these two programs. The next stage of development for PX-12 will require substantial resources and time, which would be more suitable in partnership with a larger pharmaceutical company."

"We will also continue our manufacturing and process development activities for Stimuvax," continued Dr. Kirkman. "The Phase 3 START trial of Stimuvax in non-small cell lung cancer is actively moving forward, and we expect an additional large Phase 3 trial in a new indication to be initiated later this year. To support these trials, we continue to manufacture significant quantities of Stimuvax for our partner, Merck KGaA of Darmstadt, Ger
'/>"/>

SOURCE Oncothyreon Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Oncothyreon announces receipt of notice of non-compliance with market value of listed securities standard for listing on The NASDAQ Global Market
2. Oncothyreon initiates Phase 1 trial of PX-866 cancer compound
3. Oncothyreon initiates Phase 1b trial of PX-12 in patients with advanced metastatic cancer
4. Oncothyreon to receive milestone payment
5. Oncothyreon Reports First Quarter 2008 Financial Results
6. Oncothyreon files investigational new drug application for PX-866 oncology compound
7. Data for Oncothyreons PX-12 and PX-866 presented at AACR Annual Meeting
8. Oncothyreon announces data from multiple small molecule programs to be presented at American Association of Cancer Research Annual Meeting
9. Oncothyreon announces effectiveness of shelf registration statement
10. Oncothyreon announces issuance of patent for PX-867
11. Oncothyreon to present at upcoming investment conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... Fla. , July 11, 2014 /PRNewswire-iReach/ -- Maxim ... high-quality peptides that are used solely in scientific experiments, ... two successful years in business, Maxim Peptide, which was ... just launched a new and updated website that now ... blog section has been updated with fascinating articles about ...
(Date:7/11/2014)... , July 11, 2014 /CNW/ - Sunovion Pharmaceuticals Canada ... TM (eslicarbazepine acetate) for use as a once-daily ... patients with epilepsy who are not satisfactorily controlled with ... use in patients under 18 years of age. ... neurological disorders and according to Epilepsy Canada, it affects ...
(Date:7/10/2014)... UK (PRWEB) July 10, 2014 ... 21st Century Medicine Forum on ‘Commercialising Longevity Research’ ... and entrepreneurs to the London Bioscience Innovation Center ... Research Foundation and Aging Analytics Ltd. The meeting ... investment in translational research for age-related disease, as ...
(Date:7/10/2014)... July 10, 2014 OMICS Group’s 5th ... during 18-20 August, 2014 at Double Tree by Hilton ... recent developments in Analytical & Bioanalytical research methods only ... Speaking on this occasion, Dr. Srinubabu Gedela, MD of ... conference is a remarkable one in bringing a unique ...
Breaking Biology Technology:Maxim Peptide Celebrates Second Anniversary Online with an Updated Website and Special Deals Section 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4
... Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR ) today ... Genuity Annual Growth Conference on August 10, 2011 at ... Boston. (Logo:   http://photos.prnewswire.com/prnh/20090413/LA97352LOGO ) ... accessible in the Investors section of the Company,s website ...
... of bacteria in hospitals is increasing. Bacteria acquire resistance ... incorporating new genes, either from the surrounding environment or ... Portuguese CBA research (University of Lisbon) and the Instituto ... mechanisms of resistance are playing out in the bacterium ...
... tiny hair-like structures that perform feats such as clearing ... location of organs during development, move in mysterious ways. ... similar in appearance to "the wave" created in large ... a pattern of movement around the entire stadium. ...
Cached Biology Technology:Bacterial resistance to antibiotics: The more they resist, the more they divide 2Brandeis lab's artificial cilia spur new thinking in nanotechnology 2
(Date:7/11/2014)... of kidney injury related to the use of hydroxyethyl ... HES molecules, according to a report in Anesthesia ... Research Society (IARS). , The "total mass of HES ... human renal proximal tubule cells (PTCs), concludes the laboratory ... Hospital Wrzburg, Austria. Other factorssuch as differences in ...
(Date:7/11/2014)... normal circumstances, astrocytes participate in normal physiological ... exhibit therapeutic and repairing effects on brain ... found that nerve cells differentiated from adipose-derived ... viability, which produces influences on subsequent studies ... Hospital, Hebei United University, China demonstrated that ...
(Date:7/11/2014)... to study the proteins that let nerve cells send ... stumbled upon a biological tactic that may offer a ... a safe and environmentally responsible way. , Their ... one species and harmless for a closely related onesuggests ... without harming beneficial species like bees. A summary of ...
Breaking Biology News(10 mins):In lab studies, hydroxyethyl starch has direct harmful effects on kidney cells 2Potent spider toxin 'electrocutes' German, not American, cockroaches 2Potent spider toxin 'electrocutes' German, not American, cockroaches 3
... in the world to have survived exposure to the vacuum ... Ingemar Jnsson, a researcher at Kristianstad University in Sweden. ... Jnsson had some 3,000 microscopic water bears sent up on ... project, which was supported by the European Space Agency, was ...
... September, in the context of France,s presidency of the ... at the Grand Palais. The GMES (Global Monitoring ... to provide services relating to the environment, climate change, ... on data - mainly Earth observation data - from ...
... clear skies and smooth sailing for oceanic vessels has ... to air pollution and greenhouse gas emissions that impact ... James Winebrake and James Corbett examines "Emission Tradeoffs among ... Oil, Marine Gas Oil, and Marine Diesel Oil," in ...
Cached Biology News:Major European program for the environment under the spotlight in Lille, France 2Fuel emissions from marine vessels remain a global concern 2
... The mini incubation trays ... used to screen antigens that ... membrane. Each tray has eight ... channels that accommodate strips cut ...
... analysis and experiment control software. Records ... on-line and off-line analysis. powerful stimulus ... language allowing the user to customize ... Applications range from basic data logging ...
... • Small design specifically for western ... ,Trays are specifically designed for staining western ... x 25 mm) of the disposable tray ... a significant cost savings to the user. ...
... a direct antibiotic-based selection ... Recombinant selection depends solely ... the need for costly ... and inexpensive process provides ...
Biology Products: